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ABSTRACT
THE EFFECT OF BASAL BOLUS INSULIN ADMINISTRATION VS. SLIDING
SCALE INSULIN ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2
DIABETES MELLITUS AT A COMMUNITY HOSPITAL
Evidence of effective insulin delivery by nurses can help prevent fluctuating
plasma glucose levels of Type 2 diabetes mellitus (T2DM) in the hospital setting.
Information leading to better diabetes care using either basal bolus insulin administration
(BBI) or sliding scale insulin (SSI) is essential for safe blood sugar values. The purpose
of this project was to measure patient glycemic control after the implementation of BBI
vs. SSI during a patients’ stay in the hospital. This study was a quantitative, retrospective
exploratory chart review of T2DM in medical-surgical units at a Northern California
community hospital. The data were collected from routine standardized point of care
testing documentation on an electronic record. The study timeframe of chart reviews
occurred from May 2017 to May 2018. Results suggest that SSI provided better glycemic
control in hospitalized patients with T2DM. This study showed when using SSI, the
average blood glucose was lower and that the estimated mean HgbA1c was lower in
comparison to BBI.
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CHAPTER 1: INTRODUCTION
Diabetes mellitus is a life-threatening disease with chronic long-term
complications affecting over 30 million people (Centers for Disease Control and
Prevention [CDC], 2017). Ninety-five percent of individuals with diabetes are
diagnosed with type 2 diabetes mellitus (T2DM) and 5% have type 1 diabetes. In
2015, diabetes became the seventh leading cause of death and the cost of the
disease in the United States was estimated at $245 billion (CDC, 2017).
Controlling insulin levels for diabetes is more challenging when patients are in the
hospital; insulin needs increase during acute illness or surgery because of the
physiological stress in the human body (Johnson & Van Horn, 2011). Ensuring
better glycemic control in T2DM is paramount to long-term survival.

Problem Statement
After the implementation of Basal Bolus Insulin Administration (BBI)
guidelines at a Northern California community hospital, concerns were raised if
BBI would have better glycemic control in patients with T2DM than Sliding Scale
Insulin (SSI). In 2016, the American Diabetes Association (ADA) strongly
discouraged only the use of sliding scale insulin in patients with T2DM. Instead, a
basal plus bolus correction insulin regimen was the preferred treatment (ADA,
2016). Although several researchers examined the management of T2DM patients
in the hospital setting, data on glycemic control has been difficult to record and
track for BBI vs. SSI at a Northern California community hospital. There has been
minimal research comparing glycemic control between patients managed with
BBI and SSI within the same hospital setting. The aim of this research was to

2
retrospectively review blood sugar readings between T2DM patients managed
with either BBI vs. SSI.

Purpose
The purpose of the study was to assess glycemic control following the
implementation of BBI as compared to SSI for hospitalized patients with T2DM at
a community hospital.

Background
Diabetes is a metabolic disease characterized by abnormal insulin secretion.
Type 2 diabetes mellitus (T2DM) is characterized by insufficient insulin
production. According to the American Diabetes Association (2014), T2DM
patients have an impaired and defective insulin secretion and response.
Basal bolus insulin administration (BBI) has been defined as when a patient
receives a long-acting insulin and a short-acting insulin to minimize abnormal
blood glucose levels (Umpierrez et al., 2007). For example, a patient would
receive a daily long-acting insulin and before meals rapid-acting insulin analogs
(Umpierrez et al., 2007). One disadvantage would be daily multiple injections.
Evidence suggests that using BBI improves glucose control, decreases hospital
complications, and reduces the length of stay. Umpierrez et al. (2011) found that
the application of basal-bolus insulin to T2DM patients after surgery and to noncritically ill patients showed better management of diabetes than sliding scale
insulin (SSI), a method discovered in the late 1970s for short-term use in the
hospital that was "never associated with improved clinical outcomes" (Umpierrez
et al., 2007, p. 2185). Basal-bolus insulin showed improvement in managing
diabetes, specifically by preventing hyperglycemia while patients were in the
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hospital (Umpierrez et al., 2011) and decreasing complications associated with
diabetes (Harris, Narayan, & Ali, 2015).
On the other hand, sliding scale insulin (SSI) is the oldest form in the
treatment of diabetes. In the sliding scale insulin method, the dose is based upon
the blood sugar level just before the next meal. The amount of insulin is listed in a
chart. It is based on the progression of increasing the rapid-acting or regular
insulin with the addition of scheduled insulin injections to sustain blood glucose
levels if required. The major disadvantages of using a sliding scale are that meals
should contain the same amount of carbs. In the hospital setting, meals may be
regulated by carbohydrate counts, but withholding food, changes in activity and
stress will also affect blood glucose levels. Despite disadvantages, this treatment is
commonly used in the hospital setting (Alfehaid, Alotaibi, Alanazi, Bustami, & El
Malik, 2018). The principal difference between the two strategies is that slidingscale insulin does not deliver adequate glycemic control to patients and addresses
hyperglycemia after it has occurred, whereas a basal–bolus regimen is directed at
preventing hyperglycemia (Badlani et al., 2014).
Glycemic control was defined by the American Diabetes Association’s
(ADA, 2018) official recommendations for people with diabetes—namely, (1)
fasting glucose is 80–130 mg/dL (4.4-7.2 mmol/L) and (2) 2 hours after meals it is
less than 180mg/dL (10.0mmol/L). Hypoglycemia was defined as follows:
Level 1: A glucose alert value of 3.9 mmol/l (70 mg/dl) or less.
Level 2: A glucose level of <3.0 mmol/l (<54 mg/dl) is sufficiently low to
indicate serious, clinically important hypoglycemia.
Level 3: Severe hypoglycemia, as defined by the American Diabetes
Association (2018) denotes severe cognitive impairment requiring external
assistance for recovery.
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Glycemic control is important to the patient, nurses, and the hospital for
various reasons. For the patient, good glycemic control with proper insulin
treatment minimizes microvascular complications, decrease cardiovascular
complications, and all-cause mortality. For the purpose of this study,
hypoglycemia was measured based on blood glucose levels less than 70 mg/dL
(American Diabetes Association, 2014). Lower blood glucose levels are often not
reported as much as higher blood glucose levels. It is important to have glycemic
control for T2DM patients to prevent microvascular and cardiovascular
complications and to decrease all-cause mortality (Elliott, Fidler, Ditchfield, &
Stissing, 2016). The most common feared adverse effect of diabetes insulin
therapy management is hypoglycemia. It is through proper management of
treatment modality to achieve good glycemic control ((Elliott et al., 2016).
Point-of-care testing (POCT) is defined as diagnostic type of test done at
the patient’s bedside and considered as a way to provide quick information about
the patient’s blood glucose levels (Klonoff, 2014). The recommended general
glycemic target is a glycated hemoglobin (HbA1c) level of <7 mg/dL (American
Diabetes Association, 2016). The estimated glycated hemoglobin (eAG) is a new
recommended term from the American Diabetes Association, this allowed
reporting of HbA1c results for diabetes patients, utilized same units (mg/dL or
mmol/L in day-to-day blood glucose measurements (American Diabetes
Association, n.d.).

Significance for Nurses
Nurses specializing in diabetes are key members of the inpatient care team
for the translation of research related to evidence-based diabetes practice. In May
2016, a Northern California community hospital conducted a study to understand
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nurses’ baseline diabetes patient care knowledge prior to making a treatment
change to BBI. Results showed that continued emphasis to improve and sustain
nursing knowledge on basal-bolus insulin therapy was necessary.
Recommendations included a larger enterprise-wide education program to
introduce basal-bolus insulin therapy as an ongoing educational opportunity in
order to sustain nursing knowledge gains and improve confidence levels.
In addition to providing this evidence, nurse practitioners specializing in
diabetes should be included on committees that write institutional guidelines and
policy on when and how to initiate and change/adjust insulin therapy. The clinical
management of T2DM patients in the medical-surgical units is important to the
hospital. The importance of glycemic control during the patients’ hospital stay
improves patients’ care outcomes, decreases mortality and morbidity rates, and
decreases readmissions and length of stay. Patients recover from their medical
illness and surgical patients experience better healing in surgical patients.
The Centers for Medicare and Medicaid Services (CMS) has been working
on improving quality care. CMS will focus on healthcare of Medicare
beneficiaries, and the quality measures that were helpful for quantifying processes,
outcomes, and patient perceptions. Recently, CMS developed a new way of
identifying and prioritizing measures called “Meaningful Measures” (National
Quality Forum [NQF], n.d.). The focus was to develop new medication measures
with the chance of being validated by the National Quality Forum (NQF), an
organization aimed at evaluating and supporting standardized performance
measurement. Two of the Hospital Inpatient Quality Reporting (IQR) with clinical
quality measures involve inpatients: (a) the NQF 2362, which is glycemic control–
hyperglycemia and (b) NQF 2363, which is glycemic control–severe
hypoglycemia (NQF, n.d.).
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Another goal of conducting this project was to contribute to quality
improvement of the NQF performance standards within a Northern California
community hospital organization. By applying measure NQF 2363, the metrics of
the BBI and SSI were measured. The goal would be to raise awareness about
providing high-quality care for T2DM patients reporting glycemic control while
hospitalized.

Theoretical Framework
The implementation of BBI in a community hospital setting involves
multiple layers of systems. In fact, the use of BBI was a patient care outcome
project related to quality improvement initiatives. The investigator used two
theories for studying this phenomenon: (a) general systems theory by Ludwig von
Bertalanffy (1972) and (b) complexity theory, which was based on general
systems theory (Skyttner, 2006).
Complexity theory sees the organization as the system and the subsystems
and their interactions with the processes, outcomes, and foreseeable and
unforeseeable consequences that may occur over time (Chandler, Rycroft-Malone,
Hawkes, & Noyes, 2015). According to Johnson (2011), complexity theory
explains how the behavior of the whole, rather than its parts, result in complex
behaviors. He defined the theory as “the study of phenomena which emerge from a
collection of interacting objects” (section 1.1). Based on this concept,
communication between systems and subsystems is crucial when dealing with any
changes in clinical practices that involve patients. The advantage of complexity
theory is that it brings people together, generate debate on ideas, and develop a
framework designed to explain the organization’s changes. This approach involves
engaging disciplines when a new “attractor” is introduced and how the behaviors
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of those affected are acknowledged. Tuffin (2016) mentioned how vital it is to
collaborate rather than imposing top-down leadership. It is essential to provide
sufficient feedback and allow agreeable solutions within the organization.
It is often a challenge to convince clinicians to use a new model of care that
is evidence-based practice. The complexity theory assumes that any actions
performed are best accomplished by working on the barriers as a cohesive group.
According to Litaker et al. (2006), the group needs to consider the general
application of the clinical practice as well as its effectiveness in guiding care
management in addition to recognizing different perspectives. Interdisciplinary
relationship sessions are recommended, such as performing the assessment of the
application, identifying the domains, and building methods together.
According to Cooper and Geyer (2009), although diabetes has been known
as a complex disease, few clinicians focus on using a theoretical framework to
guide practice. Complexity theory has been criticized and considered as an “allinclusive nature of complexity seeing it as an intangible theory that fails to offer
new [ideas] to health care” (Cooper, 2009, p. 761). Some clinicians acknowledge
that the use of the old methodology in managing complex diseases failed because
a theoretical framework was not used and the interaction within the system was
not addressed. Based on two separate studies done by The Action to Control
Cardiovascular Risk in Diabetes Study Group (2008) and van der Steeg et al.
(2008), low glucose levels in high-risk T2DM patients were not recognized,
placing the diabetes population at greater risk of developing coronary artery
disease. The emergent results revealed the consequences of failing to recognize the
harmful effects of poor glycemic control. If complexity theory had been used, this
could have been prevented. Complexity theory allows for unpredictability and
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uncertainty and it permits learning and discovery within the system, thereby
enabling complexity thinking to occur (Cooper & Geyer, 2009).
What is important to know is that the critical system’s “attractors” are
important stakeholders who should be engaged at the start of the assessment and
throughout the evaluation phase. Complexity theory allows for unpredictability.
Using complexity theory allows the clinical practice and the theory to come
together, resulting in more significant outcomes, such as the prevention of
hyperglycemic and hypoglycemic events during patients’ hospital stay. BBI
requires constant evaluation to ensure that the process would be practical and
realistic in the system.

Aim of Study
The aim of the project was to assess glycemic control following BBI in
comparison to SSI in the management of T2DM in hospitalized patients.

Hypothesis
The hypothesis was that there is a significant relationship between BBI vs.
SSI for glycemic control in hospitalized patients with T2DM.
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CHAPTER 2: LITERATURE REVIEW
A literature review was undertaken to examine the efficacy of BBI and SSI
in the management of hospitalized T2DM patients. The investigator searched
databases for relevant literature on: T2DM, glycemic control, hypoglycemia,
hyperglycemia, insulin therapy, basal-bolus and sliding scale. First, research on
T2DM relevant to the effects of insulin therapy were examined. Second, studies
that involved insulin therapy provided to T2DM patients in a hospital setting were
reviewed. Third, the investigator focused on the use of BBI compared to SSI. Four
studies were selected (Fahim et al., 2015; Roberts & Godbole, 2015; Rymaszewski
& Breakwell, 2013; Umpierrez et al., 2013).
Fahim et al. (2015) conducted a prospective multiphase study to assess
newly conducted BBI dosing guidelines in the medical unit before implementing
BBI hospital-wide. The dosing guidelines were designed to check the blood
glucose (BG) levels of patients with T2DM then compare BG before and after
receiving BBI. The four phases of the study were as follows: (a) review of BBI
guidelines nationwide; (2) conduct multidisciplinary clinical staff education on the
dosing guidelines; (3) enroll 43 patients in the pilot study; and (4) conduct data
analysis using chi-square for categorical variables, paired t-test for continuous
variables, and descriptive statistics for determining demographics. Results
indicated that the total BG was 377 mg/dl values before the use of dosing
guidelines and 723 mg/dl values after.
Fahim et al. (2015) noted a statistically significant difference in the BG
parameters between pre and post BBI at the end points; the pre BBI was p < 0.5
and the post BBI was p < 0.05. There was no occurrence of diabetic ketoacidosis
or hyperosmolar hyperglycemic states. The authors revised the insulin dosing
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guideline parameters and the units per kilogram and nurses provided insulin
administration based on the dosing guidelines. The strength of the study was the
multiphase approach, which identified the BG guidelines needed to be changed
based on the results of the pilot phase. Conclusions supported having all
physicians adjusting insulin doses based on the BBI guidelines.
Roberts and Godbole (2015) also conducted a retrospective and prospective
chart review to identify the accuracy of BBI and SSI dosing administration in a
tertiary teaching hospital. The retrospective chart review was done for the SSI and
a prospective chart review for the BBI. The sample population was 46 diabetic
inpatients with less than 5 days of receiving BBI. Investigators only studied and
analyzed insulin given at 0700, 1200, and 1700. The 2100 hours insulin
administration blood glucose levels were not analyzed because it will be gone by
the next blood glucose check at 0700. The intervention was as follows: (1) the BBI
chart was used to document blood glucose levels and had detailed information of
the ordered insulin dosages; and (2) the SSI protocol was in the patient medication
administration record, which required the nurses to document the blood glucose in
different forms.
Roberts and Godbole (2015) used a chi-square to measure the correlation of
the doses that were not given and t tests to correlate the results. Results showed
more missed SSI doses than BBI, and 41 missed doses (61.3%) of SSI as
compared to the 12 medication doses of BBI (p < .001). The SSI missed doses
mainly pertained to the group at 2100, while the BBI was 0700, 1200, 1700, and
2100-hour times. They found that low doses of SSI (8.7%) and BBI (8.8%) was
almost the same at p = .96). SSI patients (2.3%) received higher medication doses
as compared to BBI patients (p = .004). The limitation of the study was the
retrospective chart review; it did not provide a full data capture on missed doses,
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uncertain if missed, documentation or no medication available. The strength of
this study was the use of BBI regimen format in the workflow making it easier to
identify missed doses in one sheet as compared to SSI where separate sheets were
required to document blood glucose levels and the insulin medications.
A classic retrospective chart review conducted by Rymaszewski and
Breakwell (2013), the differences between the BBI and SSI were investigated
using a convenience sample of 128 T2DM in-patients who were between 18-80
years old in the medical units at a teaching hospital. They reviewed BBI and SSI
regimens of patients who did not eat, abnormal glucose levels in the blood, length
of stay (LOS) and events of hypoglycemia. Patients were excluded if they received
steroids, were on oral diabetic medications or intravenous insulin, had surgery, or
were in the hospital for less than 3 days. There were three goals in this study. The
first goal was to determine the significant difference in blood glucose levels
between BBI and SSI on fasting, mean and discharge. The difference was
supported by the fasting blood glucose values, which showed SSI were higher than
BBI (SSI 201.4; BBI 135.5; p <.001), the mean blood glucose values were higher
in SSI than BBI (SSI 225; BBI 149; p,.001), and the discharge blood glucose
values of SSI were also higher than BBI (SSI 244.3; BBI 128.6; p<.001). There
were no statistically significant difference on fasting, mean, and discharge blood
glucose values. The second goal was to investigate the association of BBI and SSI
patients and their LOS. The LOS for SSI was 4.6 days while the BBI was 4.8
days; the results were not statistically significant. The third goal was to determine
if there were statistically significant differences between SSI and BBI on episodes
of hypoglycemia (mild, moderate, or severe). Hypoglycemia was defined as blood
glucose not lower than 70mg/dl or 389 mmol/l. The results were not statistically
significant. The strength of the study was the results that indicated the SSI group
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had higher fasting, mean and discharge blood glucose values in comparison to the
BBI group.
In another classic study, Umpierrez et al. (2013) looked at T2DM patients
using BBI and basal plus bolus in a six-hospital multicenter organization on the
East Coast. They enrolled 735 adult patients from the medical-surgical units using
the following criteria: (a) patients with blood glucose between 140 and 400 mg/dl
and (b) history of T2DM more than 3 months. The study included two outcome
measures to identify the differences in blood glucose levels of patients treated with
BBI, basal plus bolus, and SSI. Investigators compared the baseline of clinical
characteristics and used the Wilcoxon test to compare continuous variables and
chi-squares for distinct variables. Umpierrez et al. determined that there were no
significant differences among groups in terms of age, ethnicity, body mass index,
or length of stay in the hospital. The results revealed improved blood glucose
control and fewer treatment errors in BBI and basal plus bolus as compared to the
SSI group. A limitation of the study was that it did not distinguish among the six
hospitals. The strength of this study was to show better glycemic control in
hospitalized patients receiving BBI and basal plus bolus as compared to SSI. This
project informed the ADA’s (2016) decision to strongly discourage only the use of
sliding scale insulin only in patients with T2DM.
Several studies demonstrated the clinical benefits (Fahim et al., 2015) and
better glycemic control of using BBI over SSI (Roberts & Godbole, 2015;
Rymaszewski & Breakwell, 2013; Umpierrez et al., 2013). For example, the SSI
patients who missed their insulin doses or received higher medication doses had
more severe hyperglycemic events (Umpierrez et al., 2013). The aim of this study
was to contribute to the literature of evidence-based practice on the positive
clinical outcomes of hospitalized patient glycemic control.
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CHAPTER 3: METHODOLOGY
Research Design
The study was a descriptive quantitative chart review within a community
hospital organization. The design was a retrospective closed case review. This
study was cross-sectional with data obtained from electronic medical records from
May 2017 to May 2018.

Setting
The study was conducted in a Northern California community-based
hospital. The majority of the population is upper middle class and well educated.
The hospital serves an ethnically diverse population. The setting was multi-site as
there were two medical-surgical units at the same organization. The rationale for
choosing two campuses was due to the difference in the average number of
patients at each campus. One-unit averaged 16 patients per day and one-unit
averaged 80 patients per day. The hospital was familiar with the basal bolus
insulin recommendations from the ADA.

Sample
Inpatient electronic medical records of adult male and female patients with
T2DM were analyzed for glycemic control. The sample included 40 electronic
records for BBI and 50 electronic records for SSI patients conducted as a
retrospective closed medical chart review. The inclusion criteria were as follows:
(a) adult patients with known T2DM on admission, (b) T2DM patients who
received SSI, (c) T2DM patients who received BBI, and (d) T2DM patients with
the length of stay (LOS) of fewer than 5 days discharged from medical-surgical
units. The exclusion criteria were as follows: (a) deceased T2DM patients, (b)
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patients with gestational diabetes, (c) pediatric populations, (d) Type 1 diabetes
mellitus patients, and (e) T2DM patients who were on observation status less than
24 hours stay. The sources were obtained from review of medical records as part
of a retrospective chart review (T2DM patients using ICD 10 codes, filtered by
discharged units, BBI and SSI). The SSI and the BBI groups were based on
medications given to T2DM patients.

Ethical Considerations
Patients were de-identified and coded for T2DM who received either BBI
or SSI. The data were stored in a protected electronic folder that was password
accessible only; the investigator was the only person that could access the data.
After 1 year, the medical record numbers (MRN) and the coded numbers in the
spreadsheet and all data collection sheets were destroyed.

Procedures
The Institutional Review Board (IRB) at California State University,
Fresno, School of Nursing Research Committee and the El Camino Hospital IRB
approved this project. A quantitative chart review was conducted on T2DM
patients receiving either BBI or SSI and admitted between May 2017 and May
2018. An information technology specialist reviewed electronic medical records a
de-identified the data abstracted by coding. Data were not subject to
manipulation.
Inclusion and exclusion criteria were applied. Electronic medical records
were filtered for a diagnosis of T2DM base on ICD-10 codes. Next, the subjects
who (a) received sliding scale insulin and basal bolus insulin or (b) obtained
plasma blood glucose values from point-of-care testing with glucometer from
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medical surgical locations were entered onto an electronic spreadsheet. The SSI
and the BBI groups were determined on the medications given to T2DM patients.
The SSI group selected should be in SSI only sliding scale in the medical record
administration (MAR) but for the purpose of the project should not have received
any long-acting insulin. Whereas BBI would have had both. Those who received
both BBI (with long-acting insulin) and SSI during the same admission were
excluded and did not contribute to either group.
The subjects’ age in years, gender and length of stay were noted and
entered onto an electronic spreadsheet. Point-of-care blood glucose readings were
recorded and examined for glycemic control. Finally, blood glucose readings were
averaged for the subject’s length of stay.

Data Analysis Plan
De-identified data were collected and transferred to an electronic
spreadsheet and then imported into an electronic statistical package. Data were
analyzed using descriptive statistics. Descriptive statistics provide brief
observations and summaries about the sample that help identify patterns (Conner
& Johnson, 2017). An independent samples t test was used to determine age
differences as well as length of stay between the SSI and BBI groups. A chi
squared test of association was used to determine if there were gender differences
between the SSI and BBI groups.
Point-of-care testing glucose values were averaged by readings obtained
during the subject’s length of stay. An estimated hemoglobin A1c was calculated
based on the average glucose value. The A1c-Derived Average Glucose (ADAG)
Study Group (2008) proposed the relationship between A1C and eAG is described
by the formula 28.7 X A1c – 46.7 = eAG (Nathan, et al., 2008).
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An independent samples t test was used to analyze the average blood
glucose and estimated HbA1c among the SSI and BBI groups. The level of
statistical significance for this project was p ≤ .05.
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CHAPTER 4: RESULTS
Statistical Analysis
A total of 90 electronic medical records were selected for the study based
on inclusion and exclusion criteria. Electronic medical records were then divided
into two insulin administration groups: BBI and SSI. Demographic variables of
age, gender and length of stay were compared between the two groups.
For the entire sample, the average age was 63.66 years (SD = 15.15 years)
and ranged from 24 years to 94 years. The average length of stay was 6.73 days
(SD = 9.71) and ranged from 0 to 55 days (see Table 1).
Table 1
Descriptive Statistics for Age and Length of Stay for the Entire Sample
N

Minimum

Maximum

M

SD

Age

90

24

94

63.66

15.51

Length of Stay

90

0

55

6.73

9.71

Variable

The variables of age and length of stay did not differ between the BBI and
SSI groups (see Table 2). By group, the mean age of the BBI sample was 62.85
(minimum age =24, maximum age = 94). The mean age of the SSI sample was
64.30 (minimum age = 24, maximum age = 92). As determined by an independent
samples t test, the difference in the average age of 1.45 years between the SSI and
BBI group was not statistically significant (t(88) = -0.43, p = .66). By group, the
mean length of stay for the BBI sample was 7.98 days with a minimum stay of 0
days and a maximum stay of 55 days. The mean length of stay for the SSI sample
was 5.80 days with a minimum stay of 0 days and a maximum stay of 38 days. As
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determined by an independent sample t test, the difference of 2.10 days in the
average stay between the SSI and BBI group was not statistically significant (t(88)
= 1.01, p = .31).
Table 2
Descriptive Statistics for Age and Length of Stay by Group
BBI
Variable

N Min Max

Age

40 24

Length of Stay 40

0

SSI

M

SD

N

Min Max

M

SD

94

62.85

15.75

50

24

92

64.30 15.45

55

7.90

10.85

50

0

38

5.80

8.71

For the entire sample, the subjects’ gender was 51.1% (n = 46) males and
48.9% females (n = 44); 44.4% (n = 40) assigned to the BBI group and 55.6% (n =
50) assigned to the SSI group (see Table 3).
Table 3
Frequencies and Percentages of Gender for the Entire Sample
Demographic Variables

n

%

Men

46

51.1

Women

44

48.9

Total

90

100.0

BBI

40

44.4

SSI

50

55.6

Total

90

100.0

Gender

Group
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Table 4 showed the BBI sample was composed of 50% women (n = 20) and
50% men (n = 20). The SSI sample was composed of 48% women (n = 24) and
52% males (n = 26). As determined by a chi square test of association, there were
no statistically significant differences in gender between the SSI and BBI group
(x2(1) = 0.03, p = .85.
Table 4
Frequencies and Percentages of Gender by Group
BBI

SSI

n (%)

n (%)

Men

20 (50.0)

26 (52.0)

Women

20 (50.0)

24 (48.0)

Total

40 (100.0)

50 (100.0)

Demographic Variable
Gender

There were no statistically significant differences in age, gender and length of
stay between the BBI and the SSI groups.
Average Blood Glucose
An independent-samples t test was conducted to compare average blood glucose
between the BBI and SSI groups. There was a statistically significant difference of 27.20
mg/dL in average BG for patient between the SSI (M = 175.09, SD = 40.56) group and
the BBI (M = 201.12, SD = 61.82) group, t(86) = 2.46, p = .01. There was a higher
average blood glucose level for those in the BBI group as compared to those in the SSI
group (see Table 5).
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Estimated Hemoglobin A1c
An independent-samples t test was conducted to compare estimated hemoglobin
A1c blood glucose between the BBI and SSI groups. There was a statistically significant
difference of 1.03 % found between estimated HbA1c between the BBI group (M = 8.76,
SD = 2.10) and the SSI group (M = 7.72, SD = 1.41); t (86) = 2.76, p = .007. These
results suggest a higher average estimated HbA1c for those in the BBI group as compared
to the SSI group (see Table 5).

Table 5
Independent Samples t Tests for Averages Blood Glucose and Estimated HbA1c
Variable

Instruction N

Average
BG

BBI

39 202.12 61.82 2.46

SSI

49 175.09 40.56

BBI

39

8.76

2.10

SSI

49

7.72

1.41

Estimated
HbA1c

M

SD

t

P

Mean
Difference

.01

27.02

95% CI
(Lower,
Upper)
5.24, 48.11

2.76 .007

1.03

0.29, 1.78

Note. p = .007

Results suggest that SSI provides better glycemic control. Specifically,
results suggest that when using SSI, the average blood glucose is lower (see Figure
1) and the estimated HbA1c is lower (see Figure 2) during the subjects stay in the
hospital.
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Figure 1. Average blood glucose level mg/dL comparing basal bolus insulin (BBI)
to sliding scale insulin (SSI).

Figure 2. Estimated HbA1c comparing basal bolus insulin (BBI) to sliding scale
insulin (SSI)
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CHAPTER 5: DISCUSSION
This project had many similarities and differences with prior investigations.
Between the BBI and SSI groups there were no demographic variable differences
between hospitalized patients in this study. In other words, there were no statistical
differences between groups as related to age, gender and length of stay which was
similar to other literature reviews of Rymaszewski & Breakwell, 2013, and
Umpierrez et al., 2013.
In comparison of the average blood glucose of the two groups, this study
revealed that the SSI group showed a lower average blood glucose than the BBI
group. This is contrary to several studies which demonstrated the clinical benefits
(Fahim et al., 2015) and better glycemic control of using BBI over SSI (Roberts &
Godbole, 2015; Rymaszewski & Breakwell, 2013; Umpierrez et al., 2013). In fact,
Umpierrez et al., 2013 found that SSI patients who missed their insulin doses or
received higher medication doses had more statistically significant hyperglycemic
events (Umpierrez et al., 2013).
Although the researcher was not able to determine the hypoglycemic events
in this study, Rymaszewski and Breakwell (2013) studied the effectiveness of
glycemic control with SSI and BBI and found more episodes of mild/moderate
hypoglycemic with BBI than SSI therapy, although the difference was not
statistically significant. Roberts and Godbole (2015) performed a retrospective
chart review of SSI and a prospective chart review of BBI. In the SSI retrospective
study, low doses of SSI and BBI were almost the same whereas the SSI group
received higher doses of medications than the BBI group.
In comparison with the HbA1c, a statistically significant difference
emerged, suggesting a lower average estimated HgbA1c for those in the SSI group
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as compared to the BBI group. In comparison with Rymaaszweski & Breakwell
(2013) study showed HbA1c were not different in BBI and SSI with questionable
accuracy in their HbA1c values reported.
Elliott et al. (2016) found that it is also important to use HbA1c as platform
targets to understand higher hypoglycemic event rates because patients might
present with no symptoms, patients and nurses might not notice no symptoms, and
they might underreport events. The study outcomes, which were consistent with
Elliott et al.’s (2016) findings, indicated that the retrospective chart review could
likely underestimate the real incidence of glycemic control, as compared with the
prospective study. The results showed that healthcare professionals did not report
lower blood glucose levels as often as higher blood glucose levels (Elliott et al.,
2016). Elliot et al.’s (2016) study results revealed the opposite of the stated aim
which was to compare the low BG events versus those who are reported in clinical
trials. The researchers examined the possibility and why it occurred that way.
Elliott et al. (2016) further mentioned that real-world data versus randomized
controlled trials (RCTs) can guide healthcare professionals in providing proper
management and treatment of choice to achieve glycemic control.
There could be two possible implications in this study for health care
providers. First, whether SSI or BBI order sets were used, clinicians need to
consider what type of insulin management appropriate for their patients,
individualized care based on the patient’s glycemic blood levels and presenting
signs and symptoms, looking at the patient’s overall diagnosis. Another
implications ,which was not part of this study, to consider clinicians familiarity
with SSI and BBI protocols.
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Limitations
As this study focused on a community hospital organization on two
separate units. The results of this descriptive study apply in this setting but are not
generalizable. The recent BBI implementation was a small sample size of 90
patients after the initial roll out of a new practice change. Another limitation of the
study is its internal validity. The two hospital units have different healthcare
providers (e.g., hospitalist, independent clinicians) using either SSI or BBI, and
some might find SSI to be more beneficial than BBI. The hospital had undergone
new practice changes educating the staff on BBI. Those efforts are ongoing.
Finally, the study might not have captured the data documentation of glycemic
control completely, especially when limiting or providing more supplemental
dextrose or nutritional carbohydrates.

Recommendations for Future Research
Future research should use prospective study designs for T2DM patients
receiving BBI and SSI to understand glycemic control in a hospital setting. In fact,
studies that use technology of continuous glucose monitoring would offer more
data on glycemic control. This would include more information on hyperglycemic
and hypoglycemic events. Future studies could also reveal nurses’ levels of
comfort and familiarity with BBI. As this study did not include cardiovascular
patients with T2DM in the telemetry units, conducting a study of this population is
important as T2DM places this population at high risk for co-morbidity associated
with poor outcomes if they do not control their glycemic control well (Elliot et.al,
2016). The use of advanced nurse practice nurses and nurse educators/or those
who have strong knowledge of and interest in glycemic controls for T2DM
inpatients can help improve glycemic control.
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Implications for Nursing Practice
The results of this study can provide information for nursing. It is important
that nurses evaluate their current BBI and SSI protocols and, if necessary, review
the guidelines and workflow processes. Nurses should perform evaluations once
they have implemented such changes to identify flexibility when modifying
guidelines and changing workflow as needed. As this study demonstrated, SSI
achieved better glycemic control than BBI; Therefore, more time is needed for
evaluating glycemic control and discussing patient outcomes. The use of advanced
practice nurses and on-site diabetes nurse educators or resources can provide
support not only for nurses, but also for physicians, hospitalists, external
providers, by providing inpatient consultation.

Conclusion
Providing glycemic control for T2DM patients while hospitalized is
important. Based on a comparison of average blood glucose levels and the
estimated HbA1c the SSI group had better glycemic control than the BBI group. It
may be in this community hospital setting that sliding scale insulin was more
effective than basal-bolus coverage for glycemic control. More time may be
needed to effectively evaluate a new practice change.
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